Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Video on Hot Topics in IBD
  • CME
  • CE

Credits Available
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
Registered Nurses: 0.75 Nursing contact hours
Released: November 13, 2020 Expiration: November 12, 2021
Start Activity
Provided by the American Gastroenterological Association

American Gastroenterological Association (AGA)
4930 Del Ray Avenue
Bethesda, MD 20814
Phone: (301) 654-2055
Fax: (301) 654-5920
Email: member@gastro.org

Produced in collaboration with
Supported by educational grants from
AbbVie Inc.
Gilead Sciences, Inc.
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Takeda Pharmaceuticals USA, LLC
Uma Mahadevan, MD
William Sandborn, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Develop initial IBD treatment strategies with the goal to achieve early deep remission in patients with moderate to severe disease
  • Consider the latest outcomes data on non-TNF inhibitor biologics or JAK inhibitors when considering switch therapy for patients who do not achieve sustained remission with conventional or TNF inhibitor regimens
  • Explore evidence-based strategies for IBD treatment de-escalation that may include dose reduction or drug discontinuation once sustained remission has been achieved
  • Compare and contrast JAK inhibitor selectivity for specific JAK enzymes and how these distinctions may potentially relate to safety outcomes

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Uma Mahadevan, MD

Professor of Medicine
Division of Gastroenterology
Department of Medicine
University of California, San Francisco
Co-Director
UCSF Center for Colitis and Crohn's Disease
San Francisco, California

Uma Mahadevan, MD, has disclosed that she has received consulting fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, and Takeda and funds for research support from Genentech and Pfizer.
William Sandborn, MD

Professor
Chief of Gastroenterology

Division of Gastroenterology
University of California San Diego
San Diego, California

William Sandborn, MD, has disclosed that he has received funds for research support from AbbVie, Amgen, Atlantic Healthcare Limited, Celgene/Receptos, Genentech, Gilead Sciences, Janssen, Lilly, Pfizer, Prometheus, and Takeda; that he has received consulting fees from AbbVie, Alimentiv, Allergan, Amgen, Arena, Avexegen, BeiGene, Boehringer Ingelheim, Celgene, Celltrion, Conatus, Cosmo, Escalier, Ferring, Forbion, Genentech, Gilead Sciences, Gossamer Bio, Incyte, Janssen, Kyowa Kirin Pharmaceutical Research, Landos, Lilly, Oppilan, Otsuka, Pfizer, Progenity, Prometheus, Reistone, Ritter, Seres, Shire, Sienna, Sigmoid, Sterna Biologicals, Sublimity, Takeda, Theravance, Tigenix, Tillotts, UCB Pharma, Ventyx, Vimalan, and Vivelix; that he holds stock or stock options with BeiGene, Escalier Biosciences, Gossamer Bio, Oppilan, Prometheus, Progenity, Ritter, Shoreline Biosciences, Ventyx, and Vimalan; and that his spouse has received consulting fees from Iveric and Oppilan; holds stock or stock options from Escalier Biosciences, Iveric, Oppilan, Progenity, Prometheus, Shoreline Biosciences, Ventyx, and Vimalan; and is employed by Prometheus.

Staff

Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.
Julie Skowronski, FNP-BC
Julie Skowronski, MSN, has no relevant conflicts of interest to report.
Carolyn Skowronski, PharmD

Associate Director, Scientific Services

Carolyn Skowronski, PharmD, has no relevant conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The American Gastroenterological Association, Clinical Care Options, and the activity supporter do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the American Gastroenterological Association, Clinical Care Options, and the activity supporter. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

Gastroenterologists, nurses, and other healthcare providers who care for patients with IBD.

Goal

Improve clinicians’ competence in navigating the most challenging clinical issues to help ensure successful IBD care.

Physician Continuing Medical Education

Accreditation Statement

The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The AGA Institute designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO) and the American Gastroenterological Association. Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hours.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 13, 2020, through November 12, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Video on Hot Topics in IBD
  • CME
  • CE

Loading...
Hear expert insights on optimal management of inflammatory bowel disease, strategies for achieving deep remission, and the latest data on biologics and JAK inhibitors.
Uma Mahadevan, MD
William Sandborn, MD
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
Registered Nurses: 0.75 Nursing contact hours
Released: November 13, 2020 Expiration: November 12, 2021

Related Content

Expert commentary from Dr. Bruce Sands on therapeutic drug monitoring in IBD, from Clinical Care Options (CCO)

Bruce E. Sands, MD, MS Released: June 3, 2021

Interactive video from Dr. Bruce Sands and Clinical Care Options (CCO): IBD management after TNF inhibitor failure

Bruce E. Sands, MD, MS Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: May 24, 2021 Expired: May 23, 2022

Downloadable slides covering current guideline recommendations for managing TNF-α inhibitor failure in moderate to severe UC and CD

Bruce E. Sands, MD, MS Released: May 24, 2021

Expert commentary from Dr. Bruce Sands on STRIDE-II recommendations for treat-to-target goals in IBD, from Clinical Care Options (CCO)

Bruce E. Sands, MD, MS Released: May 5, 2021
Provided by the American Gastroenterological Association

American Gastroenterological Association (AGA)
4930 Del Ray Avenue
Bethesda, MD 20814
Phone: (301) 654-2055
Fax: (301) 654-5920
Email: member@gastro.org

Produced in collaboration with
Supported by educational grants from
AbbVie Inc.
Gilead Sciences, Inc.
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Takeda Pharmaceuticals USA, LLC

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue